The FDA approves generic drugs through the ANDA pathway under the Hatch-Waxman Act, ensuring they match brand-name drugs in safety, strength, and bioequivalence. Learn how the legal and scientific process makes generics affordable without compromising quality.
Bioequivalence for inhalers, patches, and injections ensures generic drugs work like the originals-not just in blood levels, but in how they're delivered. Learn how regulators test these complex systems and why it matters for patient safety.